Jeremie Lincy

3.9k total citations · 2 hit papers
19 papers, 2.9k citations indexed

About

Jeremie Lincy is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Jeremie Lincy has authored 19 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in Jeremie Lincy's work include Neuroendocrine Tumor Research Advances (11 papers), Lung Cancer Research Studies (10 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Jeremie Lincy is often cited by papers focused on Neuroendocrine Tumor Research Advances (11 papers), Lung Cancer Research Studies (10 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Jeremie Lincy collaborates with scholars based in United States, Switzerland and Japan. Jeremie Lincy's co-authors include David Lebwohl, James C. Yao, Edward M. Wolin, Eric Van Cutsem, Tetsuhide Ito, Timothy J. Hobday, Marianne Pavel, Paola Tomassetti, Kjell Öberg and Elisabeth G.E. de Vries and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jeremie Lincy

19 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

2011 2.1k citations James C. Yao, Manisha H. Shah et al. New England Journal of Medicine profile →
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

2013 629 citations John J. Bissler, J.C. Kingswood et al. The Lancet profile →

Peers

Countries citing papers authored by Jeremie Lincy

Since Specialization

Citations

This map shows the geographic impact of Jeremie Lincy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremie Lincy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremie Lincy more than expected).

Fields of papers citing papers by Jeremie Lincy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremie Lincy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremie Lincy. The network helps show where Jeremie Lincy may publish in the future.

Co-authorship network of co-authors of Jeremie Lincy

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremie Lincy. A scholar is included among the top collaborators of Jeremie Lincy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremie Lincy. Jeremie Lincy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials 2023 ·Blood ·Abdullah Kutlar, (unknown), Andreas Brueckner, Julie Kanter, Darla Liles, Jeremie Lincy, (unknown), (unknown), Matthew M. Heeney, Mariane de Montalembert, Deborah Keefe, Kwaku Marfo, Kenneth I. Ataga	1
2	Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study 2019 ·Blood ·Kenneth I. Ataga, Abdullah Kutlar, Laurie DeBonnett, Jeremie Lincy, Julie Kanter	6
3	Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies 2019 ·Blood ·Julie Kanter, Darla Liles, Kim Smith‐Whitley, R. Clark Brown, Abdullah Kutlar, Brian Elliott, (unknown), Jeremie Lincy, (unknown), Kenneth I. Ataga	6
4	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary 2017 ·Neuroendocrinology ·Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiří Tomášek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Edward M. Wolin, Natsuko Okita, Steven K. Libutti, Do‐Youn Oh, Matthew H. Kulke, Jonathan Strosberg, James C. Yao, Marianne Pavel, Nicola Fazio, (unknown)	38
5	Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1 2017 ·Cancer Research ·Denise A. Yardley, Sara A. Hurvitz, (unknown), Masakazu Toi, Howard A. Burris, Marc Buyse, Dennis J. Slamon, А. Н. Махсон, A. Elsaid, Guillermo Lerzo, Beth A. Hellerstedt, Francesco Nuzzo, Joohyuk Sohn, L. V. Manzyuk, (unknown), Jeremie Lincy, Arved Weimann, (unknown), Lida Pacaud, Fabrice André	3
6	Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis. 2016 ·PubMed ·(unknown), Carlo Carnaghi, Roberto Buzzoni, Markus Raderer, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Pacaud, Jeremie Lincy, Natsuko Okita, Michael Kulke, (unknown), Ji‐Jin Yao, Marianne Pavel, Nicola Fazio	4
7	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study. 2016 ·Journal of Clinical Oncology ·James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel, (unknown)	6
8	Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial. 2016 ·Journal of Clinical Oncology ·Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiří Tomášek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Carolin Sachs, Natsuko Okita, Steven K. Libutti, Do‐Youn Oh, Matthew H. Kulke, Jonathan Strosberg, James C. Yao, Marianne Pavel, Nicola Fazio, (unknown)	6
9	134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract 2015 ·Annals of Oncology ·James C. Yao, Simron Singh, Edward M. Wolin, Maurizio Voi, Lida Pacaud, Jeremie Lincy, (unknown), Juan W. Valle, Eric Van Cutsem, Yoshifumi Shimada, Do‐Youn Oh	2
10	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy 2013 ·Breast Cancer Research and Treatment ·Sara A. Hurvitz, Florence Dalenc, Mario Campone, Ruth O’Regan, Vivianne C. G. Tjan‐Heijnen, Joseph Gligorov, Antonio Llombart‐Cussac, Haresh Jhangiani, Hamid Mirshahidi, Elizabeth Tan-Chiu, Sara Miao, Mona El-Hashimy, Jeremie Lincy, Tetiana Taran, Jean‐Charles Soria, Tarek Sahmoud, Fabrice André	58
11	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial breakdown → 2013 ·The Lancet ·John J. Bissler, J.C. Kingswood, Elżbieta Radzikowska, Bernard A. Zonnenberg, Michael Frost, Е. Д. Белоусова, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J. de Vries, Vicky Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde	629
12	Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM). 2012 ·Journal of Clinical Oncology ·John J. Bissler, Christopher Kingswood, Bernard A. Zonnenberg, Michael Frost, Elena Belousova, Elżbieta Radzikowska, Matthias Sauter, Norio Nonomura, (unknown), Petrus de Vries, Judith Klimovsky, Gaurav Shah, Sara Miao, Jeremie Lincy, Klemens Budde	1
13	Renal cancer and the kidney in cancer 2012 ·Nephrology Dialysis Transplantation ·Bernard A. Zonnenberg, Klemens Budde, Christopher Kingswood, Michael Frost, (unknown), Elżbieta Radzikowska, (unknown), Norio Nonomura, Susanne Brakemeier, Petrus de Vries, Judith Klimovsky, Gaurav Shah, Sara Miao, Jeremie Lincy, John J. Bissler, Bruno Walther, (unknown), (unknown)	1
14	Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) 2011 ·Pancreas ·Manisha H. Shah, Kjell Öberg, Tetsuhide Ito, Catherine Lombard‐Bohas, Edward M. Wolin, Eric Van Cutsem, Carolin Sachs, Robert Winkler, Jeremie Lincy, (unknown), James C. Yao	1
15	Everolimus for Advanced Pancreatic Neuroendocrine Tumors breakdown → 2011 ·New England Journal of Medicine ·James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg	2078
16	Updated Results from the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET) 2011 ·The American Journal of Gastroenterology ·Edward M. Wolin, Rodney F. Pommier, Jeremie Lincy, Robert Winkler, James C. Yao	1
17	Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. 2011 ·Journal of Clinical Oncology ·(unknown), Catherine Lombard‐Bohas, Tetsuhide Ito, Edward M. Wolin, Eric Van Cutsem, (unknown), Robert Winkler, Jeremie Lincy, Timothy J. Hobday, James C. Yao	18
18	6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET) 2011 ·European Journal of Cancer ·Catherine Lombard‐Bohas, Eric Van Cutsem, Jaume Capdevila, (unknown), Paola Tomassetti, Jeremie Lincy, Robert Winkler, Timothy J. Hobday, Rodney F. Pommier, James C. Yao	2
19	Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). 2011 ·Journal of Clinical Oncology ·(unknown), Tetsuhide Ito, Catherine Lombard‐Bohas, Edward M. Wolin, Eric Van Cutsem, (unknown), Robert Winkler, Jeremie Lincy, Timothy J. Hobday, James C. Yao	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact